Failure for Tarceva plus Nexavar in HCC after no survival benefit shown over Nexavar alone
This article was originally published in Scrip
Astellas/Roche's Tarceva (erlotinib) when added to Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) did not improve overall survival compared with Nexavar alone in patients with unresectable hepatocellular carcinoma (HCC).
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.